1. In Vivo
  2. >>Innovation

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

 
• By Ashley Yeo

The quality of clinical trials and data analysis have come a long way in the past 10 years – and even in the past three, says Christian Hebenstreit of Medidata, the cloud-based platform that supports pharma and medtech companies through clinical studies ahead of their commercial uptake. The buzzwords of the fairly recent past are now being applied as real tools in the clinical trials arena, and look set to transform the sector.

The London arm of Medidata NEXT, the seven-venue awareness event for clinical trials professionals around the globe, is humming with industry players keen to hear how they can use Medidata Solutions Inc.'s Clinical Cloud tool, which combines science and the operation of clinical trials. At the podium, US product development executive Dave Metz is explaining the MEDS (Medidata Enterprise Data Store) element of the offering: the repository of clinical and operational data that are the basis of clinical process decision-making.

Metz's tone is irrepressibly upbeat: Medidata's service offerings to clinical clients are increasing in speed and quality across the industry. And investors are similarly optimistic: the group has something of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.